Cyberonics, Inc.  

(Public, NASDAQ:CYBX)   Watch this stock  
Find more results for CYBX
51.02
-0.55 (-1.07%)
Jun 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 51.00 - 51.59
52 week 42.25 - 56.73
Open 51.41
Vol / Avg. 154,382.00/396,125.00
Mkt cap 1.41B
P/E 30.84
Div/yield     -
EPS 1.65
Shares 27.70M
Beta 0.70
Inst. own 102%
Aug 26, 2013
Q1 2014 Cyberonics Earnings Release Add to calendar
Jun 18, 2013
Cyberonics at Northcoast Research Healthcare Forum
Jun 12, 2013
Cyberonics at Goldman Sachs Healthcare Conference
Jun 11, 2013
Cyberonics at William Blair Growth Stock Conference
Jun 6, 2013
Cyberonics at Jefferies Global Healthcare Conference
Jun 5, 2013
Q4 2013 Cyberonics Earnings Conference Call
Jun 3, 2013
Q4 2013 Cyberonics Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Apr '13) 2013
Net profit margin 16.87% 18.23%
Operating margin 29.94% 30.81%
EBITD margin - 32.97%
Return on average assets 17.98% 19.48%
Return on average equity 20.38% 22.45%
Employees 536 -
Carbon Disclosure Rating - -

Address

The Cyberonics Building 100 Cyberonics Boulevard
HOUSTON, TX 77058
United States - Map
+1-281-2287200 (Phone)
+1-281-2189332 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

Cyberonics, Inc. (Cyberonics) is a medical device company. The Company is engaged in the design, development, sales and marketing of implantable medical devices that provide a neuromodulation therapy, vagus nerve stimulation therapy (VNS Therapy), for the treatment of refractory epilepsy and treatment-resistant depression (TRD) and other device solutions for the management of epilepsy.VNS Therapy System includes an implantable pulse generator to provide stimulation to the vagus nerve; a lead that connects the generator to the vagus nerve; equipment to assist with implantation surgery; equipment to assist with setting the stimulation parameters for each patient; instruction manuals, and magnets to suspend or induce stimulation manually. The VNS Therapy pulse generator and lead are surgically implanted into patients generally during an outpatient procedure. The VNS Therapy System consists of a pulse generator, a bipolar lead, a programming wand and software and a tunneling tool.

Officers and directors

Daniel J. Moore President, Chief Executive Officer, Director
Bio & Compensation  - Reuters
Gregory H. Browne Chief Financial Officer, Senior Vice President - Finance
Age: 59
Bio & Compensation  - Reuters
David S. Wise Senior Vice President, Chief Administrative Officer, Secretary
Age: 57
Bio & Compensation  - Reuters
Milton Mayo Morris Ph.D. Senior Vice President - Research & Development
Age: 42
Bio & Compensation  - Reuters
Darren W. Alch Chief Compliance Officer, Vice President, General Counsel, Assistant Secretary
Age: 46
Bio & Compensation  - Reuters
Randal L. Simpson Vice President - Operations
Age: 52
Bio & Compensation  - Reuters
Mark S. Verratti Vice President - Global Sales
Age: 44
Bio & Compensation  - Reuters
Bruce H. KenKnight PhD Vice President - Emerging Therapies
Bio & Compensation  - Reuters
Bryan D. Olin Ph.D. Vice President - Clinical , Quality & Regulatory Affairs
Age: 45
Bio & Compensation  - Reuters
Hugh M. Morrison Non-Executive Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters